Find a UK-based prescribing clinician for medical cannabis.
Legal Requirements for Controlled Drug Labels
- All dispensed cannabis products must be labelled in accordance with the Human Medicines Regulations 2012
- Labels must include: patient name, prescriber name, name and address of the dispensing pharmacy, date dispensed
- Product description: drug name, form, strength, and quantity — must match the prescription precisely
- “Keep out of reach and sight of children” and “Store below 25°C” advisory statements are mandatory for all cannabis products
The labelling of dispensed cannabis is a legal requirement that carries the same force as for any other prescribed medication. Unlike pharmaceutical drugs, cannabis products are often dispensed in their original manufacturer’s packaging with an additional dispensing label applied. Both the manufacturer’s product information and the dispensing label must be present and legible at the time of dispensing.
Product-Specific Labelling Requirements for Cannabis Flower
- Total THC and CBD content expressed as percentage of dry weight (e.g., THC 20%, CBD 1%)
- Strain name and phenotype where known
- Total weight in grams, consistent with the prescribed quantity
- Batch number traceable to the Certificate of Analysis — enables recall if product quality issues arise
Cannabis flower is unique among dispensed medications in that its cannabinoid content varies by batch, and the dispensed product is not identical in chemical composition to other batches of the same strain. This variability makes batch-specific labelling — particularly the batch number linking to the CoA — a clinical necessity, not merely a regulatory formality. If a patient experiences an adverse event, the ability to trace the exact batch they were using is essential for investigation.
Oil and Extract Labelling: Specific Considerations
- Cannabinoid content must be expressed per unit dose (e.g., per ml, per capsule) as well as total product content
- Volume or number of capsules must be clearly stated
- Dosing instructions must specify the prescribed dose and the maximum daily dose explicitly
- Flavouring or excipient information must be included for patients with known allergies or dietary requirements
Oil preparations present specific labelling challenges because the concentration of cannabinoids can vary significantly between products, and patients need to understand how much oil to take per dose. Labelling that states only the total cannabinoid content of the bottle without a per-dose breakdown is inadequate and may lead to significant dosing errors. Pharmacists should verify that the dispensing label clearly communicates the dose in terms the patient can act on.
Patient Information Leaflets and Additional Documentation
- A patient information leaflet (PIL) should accompany every cannabis dispensing, even for repeat prescriptions
- PILs should include: how to use, side effects, drug interactions, driving advice, and when to contact the clinic
- Safe storage instructions must be included as a separate advisory, not buried in the PIL
- Dispensing records must document that the PIL was provided — this is a safeguarding as well as a compliance requirement
The provision of a patient information leaflet is not merely a paperwork exercise. For many cannabis patients, the PIL is the primary written reference they use when questions arise between clinical appointments. A well-designed PIL, updated to reflect the current evidence base and regulatory requirements, supports patient safety and contributes to the overall quality of care provided by the dispensing pharmacy.
